Biotech Values

[DewDiligence]

3Q17 worldwide Botox sales=$775M, +12% YoY (-5% QoQ*):

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNjM5NjJ8Q2hpbGRJRD02ODMxNjA=

• US therapeutic: $368.9M (+15% YoY)
• US cosmetic: $189.7M (+8% YoY)
• Ex-US therapeutic: $84.4M (+5% YoY in local currency)
• Ex-US cosmetic: $131.5M (+15% YoY in local currency)

All told, 72% of Botox sales were in the US, where the therapeutic/cosmetic split was 66/34; 28% of Botox sales were ex-US, where the therapeutic/cosmetic split was 39/61.

*The 3Q17 sales decline vs 2Q17 was expected; for cosmetic indications, the second and fourth quarters are seasonally stronger than the first and third quarters.